Business Description
XORTX Therapeutics Inc
NAICS : 325412
SIC : 3741
ISIN : CA98420Q1081
Compare
Compare
Traded in other countries / regions
XRTX.CanadaXRTX.USAANUA.Germany IPO Date
2015-10-07Description
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 36.68 | |||||
| Equity-to-Asset | 0.56 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -33 | |||||
| 3-Year EPS without NRI Growth Rate | -30.7 | |||||
| 3-Year FCF Growth Rate | -64.6 | |||||
| 3-Year Book Growth Rate | 23.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 30.29 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.86 | |||||
| 9-Day RSI | 40.36 | |||||
| 14-Day RSI | 42.99 | |||||
| 6-1 Month Momentum % | -35.62 | |||||
| 12-1 Month Momentum % | -42.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.43 | |||||
| Quick Ratio | 6.43 | |||||
| Cash Ratio | 5.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -37.5 | |||||
| Shareholder Yield % | -39.34 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -32.47 | |||||
| ROA % | -24.57 | |||||
| ROIC % | -309.12 | |||||
| 3-Year ROIIC % | -548.27 | |||||
| ROC (Joel Greenblatt) % | -2352.1 | |||||
| ROCE % | -87.15 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.64 | |||||
| Price-to-Tangible-Book | 1.57 | |||||
| EV-to-EBIT | -0.28 | |||||
| EV-to-EBITDA | -0.29 | |||||
| EV-to-FCF | -0.43 | |||||
| Price-to-Net-Current-Asset-Value | 3.18 | |||||
| Price-to-Net-Cash | 4.17 | |||||
| Earnings Yield (Greenblatt) % | -357.79 | |||||
| FCF Yield % | -99.16 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
XORTX Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.466 | ||
| Beta | 0.26 | ||
| Volatility % | 78.14 | ||
| 14-Day RSI | 42.99 | ||
| 14-Day ATR (€) | 0.14302 | ||
| 20-Day SMA (€) | 1.467 | ||
| 12-1 Month Momentum % | -42.19 | ||
| 52-Week Range (€) | 0.3 - 6.76 | ||
| Shares Outstanding (Mil) | 3.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
XORTX Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
XORTX Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
XORTX Therapeutics Inc Frequently Asked Questions
What is XORTX Therapeutics Inc(FRA:ANUA)'s stock price today?
The current price of FRA:ANUA is €1.21. The 52 week high of FRA:ANUA is €6.76 and 52 week low is €0.30.
When is next earnings date of XORTX Therapeutics Inc(FRA:ANUA)?
The next earnings date of XORTX Therapeutics Inc(FRA:ANUA) is .
Does XORTX Therapeutics Inc(FRA:ANUA) pay dividends? If so, how much?
XORTX Therapeutics Inc(FRA:ANUA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers